KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Short-term Investments (2016 - 2026)

Gsk has reported Short-term Investments over the past 18 years, most recently at -$258.9 million for Q1 2026.

  • For Q1 2026, Short-term Investments fell 316.33% year-over-year to -$258.9 million; the TTM value through Mar 2026 reached -$258.9 million, down 316.33%, while the annual FY2025 figure was $161.0 million, 15.05% up from the prior year.
  • Short-term Investments for Q1 2026 was -$258.9 million at Gsk, down from $161.0 million in the prior quarter.
  • Over five years, Short-term Investments peaked at $4.8 billion in Q4 2022 and troughed at -$383.0 million in Q3 2022.
  • A 5-year average of $461.9 million and a median of $132.2 million in 2022 define the central range for Short-term Investments.
  • Biggest five-year swings in Short-term Investments: skyrocketed 639.2% in 2023 and later crashed 3033.85% in 2025.
  • Year by year, Short-term Investments stood at $4.8 billion in 2022, then plummeted by 42.94% to $2.7 billion in 2023, then tumbled by 94.89% to $139.9 million in 2024, then rose by 15.05% to $161.0 million in 2025, then tumbled by 260.83% to -$258.9 million in 2026.
  • Business Quant data shows Short-term Investments for GSK at -$258.9 million in Q1 2026, $161.0 million in Q4 2025, and -$152.5 million in Q3 2025.